Market revenue in 2023 | USD 1,376.7 million |
Market revenue in 2030 | USD 3,277.9 million |
Growth rate | 13.2% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.01% in 2023. Horizon Databook has segmented the Spain precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
Spain's precision medicine market is expected to witness significant growth over the forecast period owing to strategies being implemented along with initiatives being undertaken by key companies in Spain. For instance, in April 2023, Fujitsu Limited collaborated with Barcelona Supercomputing Center (Spain) to promote research on personalized medicine and quantum computing.
This initiative supported the development of personalized medicine, thereby boosting the company’s growth in Spain. The Spanish government is proactively undertaking initiatives to support the adoption of personalized medicine in the country.
For instance, in September 2020, the government approved the launch of IMPaCT, the new precision medicine infrastructure. Under this program, funding of USD 84.3 million (EUR 77.3 million) has been approved with more funding planned in the next phases. Such initiatives support the growth of personalized medicine in Spain.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Spain precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account